Categories: Research

Michael Fischbach, PhD, who studies drug-like molecules produced by human gut bacteria, has been awarded one the 16 prestigious 2011 Packard Fellowships in Science and Engineering.

Bo Huang, PhD, a faculty member of the UCSF School of Pharmacy, Department of Pharmaceutical Chemistry, has been named a recipient of a 2011 National Institutes of Health (NIH) Director’s New Innovator Award.

Pharmaceutical companies will increasingly apply the predictive modeling of quantitative pharmacology to do more efficient drug development, says Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department

Adam Abate, PhD, a faculty member in the UCSF Schools of Pharmacy and Medicine, Department of Bioengineering and Therapeutic Sciences, is a prime trial candidate for QB3’s Startup in a Box.

An analysis by UCSF faculty members from the Schools of Pharmacy and Medicine has found that the half-dozen most reputable electronic drug information resources—tools commonly used by clinicians to make prescription and patient monitoring decisions—may not provide key elements of some medications’...

The new UCSF Center for Quantitative Pharmacology housed within the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department of the Schools of Pharmacy and Medicine, will be inaugurated next week with a wide-ranging, 2-day conference, September 22 and 23, 2011 at William J. ...

A novel gene associated with the asthma susceptibility in African Americans was revealed by a U.S. consortium of asthma genetics researchers, including Esteban G. Burchard, MD, MPH, Department of Bioengineering and Therapeutic Sciences,

The 2nd Annual Bay Area Biotechnology Symposium, presented by the UCSF School of Pharmacy’s Industry Outreach Program in coordination with the UCSF Postdoctoral Scholars Association at Mission Bay in late May 2011, fully lived up to its billing: “Pharmaceuticals of the Futur

Daniel Gray, PhD, is the recipient of the 2011 Julius R. and Patricia A. Krevans Distinguished Dissertation Award.

Magnetic resonance imaging (MRI), used with a novel pyruvate chemical compound that is specially labeled to be read by the MRI machine, is being applied for the first time in humans to study the aggressiveness of prostate cancer in patients and the success of prostate cancer therapies.